May 7 (Reuters) - Alvotech SA ALVO.O:
POTENTIAL U.S. TARIFFS ON PHARMACEUTICALS EXPECTED TO HAVE MINIMAL IMPACT ON ALVOTECH'S PRODUCT REVENUES IN 2025
ALVOTECH MANUFACTURES ITS BIOSIMILARS IN ICELAND, A COUNTRY WHICH CURRENTLY FACES MINIMUM TARIFF OF 10% ON GOODS IMPORTED TO U.S
A 10% TARIFF ON PHARMACEUTICALS WOULD RAISE COST OF BIOSIMILARS FROM ALVOTECH IMPORTED TO U.S. FOR CUSTOMERS BY LESS THAN 1% OF ALVOTECH'S EXPECTED TOTAL PRODUCT REVENUES IN 2025
Source text: ID:nGNEKfYb3
Further company coverage: ALVO.O
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.